Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix. Launches throughout the EU and other countries have been staggered over 2014–16, while Trintellix remains in Phase III development in Japan. Trintellix was rebranded in the US in 2016 to distinguish itself from Brilinta (ticagrelor; AstraZeneca/The Medicines Company), after reports of medication confusion by healthcare professionals.
Trintellix was first discovered by Lundbeck and then co-developed with Takeda, which now markets the drug in the US. Trintellix is a multimodal serotonergic enhancer with activity at the serotonin receptors 5-HT3, 5-HT7, 5-HT1A, and 5-HT1B, and also at the serotonin transporter. This broad pharmacological profile results in an antidepressant activity and also the potential to improve cognitive performance among depressed patients.
LIST OF FIGURES
14 Figure 1: Datamonitor Healthcare’s drug assessment summary of Trintellix for depression
15 Figure 2: Datamonitor Healthcare’s drug assessment summary of Trintellix for depression
17 Figure 3: Trintellix sales for depression across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Trintellix drug profile
6 Table 2: Approval history of Trintellix for depression in the US and five major EU markets
7 Table 3: Late-phase trials of Trintellix for depression
13 Table 4: Trintellix ongoing Phase III trials in depression
14 Table 5: Trintellix for depression – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.